Amgen Inc.

306.93
1.16 (0.38%)
At close: Mar 28, 2025, 3:59 PM
306.00
-0.30%
After-hours: Mar 28, 2025, 06:48 PM EDT

Amgen Inc. Revenue Breakdown

Quarter Sep 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018
Aranesp Revenue 337M 349M 319M 323M 365M 355M 348M 358M 357M 358M 362M 396M 367M 355M 384M 387M 422M 452M 436M 414M 477M 472M 454M
Aranesp Revenue Growth -3.44% +9.40% -1.24% -11.51% +2.82% +2.01% -2.79% +0.28% -0.28% -1.10% -8.59% +7.90% +3.38% -7.55% -0.78% -8.29% -6.64% +3.67% +5.31% -13.21% +1.06% +3.96% n/a
BLINCYTO Revenue 327M 244M 1.01B 1.03B 1.07B 579M 1.1B 1.11B 1.05B 862M 1.11B 1.29B 1.14B 924M 1.32B 1.25B 1.15B 1.37B 1.36B 1.15B 1.29B 1.3B 1.1B
BLINCYTO Revenue Growth +34.02% -75.96% -1.93% -3.09% +84.46% -47.27% -0.72% +5.23% +21.93% -22.20% -14.04% +12.67% +23.81% -30.26% +6.34% +8.07% -15.59% +0.22% +18.42% -10.91% -0.77% +17.83% n/a
ENBREL Revenue 825M 567M 350M 307M 281M 254M 325M 318M 317M 287M 284M 293M 280M 251M 260M 253M 280M 266M 267M 245M 532M 610M 494M
ENBREL Revenue Growth +45.50% +62.00% +14.01% +9.25% +10.63% -21.85% +2.20% +0.32% +10.45% +1.06% -3.07% +4.64% +11.55% -3.46% +2.77% -9.64% +5.26% -0.37% +8.98% -53.95% -12.79% +23.48% n/a
EVENITY Revenue 399M 342M 386M 349M 346M 358M 469M 288M 284M 266M 630M 609M 534M 476M 538M 561M 479M 630M 698M 592M 433M 452M 445M
EVENITY Revenue Growth +16.67% -11.40% +10.60% +0.87% -3.35% -23.67% +62.85% +1.41% +6.77% -57.78% +3.45% +14.04% +12.18% -11.52% -4.10% +17.12% -23.97% -9.74% +17.91% +36.72% -4.20% +1.57% n/a
KRYSTEXXA Revenue 310M 235M 629M 419M 310M 362M 616M 627M 594M 451M 873M 803M 814M 758M 701M 659M 654M 476M 499M 471M n/a n/a n/a
KRYSTEXXA Revenue Growth +31.91% -62.64% +50.12% +35.16% -14.36% -41.23% -1.75% +5.56% +31.71% -48.34% +8.72% -1.35% +7.39% +8.13% +6.37% +0.76% +37.39% -4.61% +5.94% n/a n/a n/a n/a
Kyprolis Revenue 378M 376M 1.11B 567M 600M 392M 992M 862M 922M 852M 273M 272M 286M 286M 205M 200M 229M n/a n/a n/a n/a n/a n/a
Kyprolis Revenue Growth +0.53% -66.03% +95.24% -5.50% +53.06% -60.48% +15.08% -6.51% +8.22% +212.09% +0.37% -4.90% 0.00% +39.51% +2.50% -12.66% n/a n/a n/a n/a n/a n/a n/a
Nplate Revenue 456M 317M 417M 986M 1.03B 927M 333M 309M 325M 329M 545M 517M 488M 468M 481M 435M 481M n/a n/a n/a n/a n/a n/a
Nplate Revenue Growth +43.85% -23.98% -57.71% -4.09% +10.90% +178.38% +7.77% -4.92% -1.22% -39.63% +5.42% +5.94% +4.27% -2.70% +10.57% -9.56% n/a n/a n/a n/a n/a n/a n/a
Otezla Revenue 564M 394M 527M 406M 424M 388M 484M 495M 533M 502M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Otezla Revenue Growth +43.15% -25.24% +29.80% -4.25% +9.28% -19.83% -2.22% -7.13% +6.18% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Prolia Revenue 1.04B 999M n/a 519M 530M 536M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Prolia Revenue Growth +4.60% n/a n/a -2.08% -1.12% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Repatha (evolocumab) Revenue 567M 517M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Repatha (evolocumab) Revenue Growth +9.67% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEPEZZA Revenue 488M 424M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEPEZZA Revenue Growth +15.09% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEZSPIRE Revenue 269M 173M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEZSPIRE Revenue Growth +55.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vectibix Revenue 282M 247M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vectibix Revenue Growth +14.17% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
XGEVA Revenue 541M 561M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
XGEVA Revenue Growth -3.57% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2011
Non-Us Revenue 8.38B 7.73B 7.79B 6.93B 6.14B 5.39B 4.82B 4.67B 4.5B 4.67B 4.2B 1.32B
Non-Us Revenue Growth +8.49% -0.73% +12.37% +12.87% +13.90% +11.80% +3.32% +3.78% -3.69% +11.22% +218.60% n/a
United States Revenue 19.81B 18.59B 18.19B 18.5B 17.22B 18.36B 18.03B 18.33B 17.17B 15.4B 14.48B 3.7B
United States Revenue Growth +6.51% +2.20% -1.63% +7.39% -6.18% +1.82% -1.62% +6.75% +11.50% +6.33% +291.25% n/a

Operating Expense Breakdown

Quarter Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 1.88B 1.63B 1.78B 1.81B 2.27B 1.35B 1.29B 1.26B 1.57B 1.29B 1.33B 1.23B 1.43B 1.3B 1.38B 1.25B 1.77B 1.35B 1.29B 1.32B 1.51B 1.22B 1.26B 1.15B 1.56B 1.29B 1.35B 1.13B 1.43B 1.17B 1.21B 1.06B 1.32B 1.24B 1.29B 1.2B 1.42B 1.24B 1.16B 1.03B
Selling, General, and Administrative Revenue Growth +15.57% -8.96% -1.27% -20.49% +68.07% +4.56% +2.86% -19.97% +22.14% -3.01% +8.06% -13.82% +9.20% -5.71% +10.37% -29.27% +31.72% +3.94% -1.60% -13.02% +23.71% -2.94% +9.19% -25.98% +20.57% -4.43% +20.05% -21.02% +21.97% -3.23% +13.63% -19.58% +6.35% -3.72% +7.40% -15.04% +13.83% +7.24% +13.06% n/a
Research and Development Revenue 1.72B 1.45B 1.45B 1.34B 1.53B 1.08B 1.11B 1.06B 1.32B 1.11B 1.04B 959M 1.35B 1.42B 1.08B 967M 1.23B 1.06B 964M 952M 1.31B 1B 924M 879M 1.18B 926M 869M 760M 1.04B 877M 873M 769M 1.08B 990M 900M 872M 1.09B 1.12B 964M 894M
Research and Development Revenue Growth +18.90% +0.21% +7.74% -12.45% +42.17% -3.05% +5.20% -20.09% +19.06% +7.03% +8.34% -28.86% -5.20% +31.42% +11.89% -21.32% +15.73% +10.17% +1.26% -27.44% +31.07% +8.33% +5.12% -25.63% +27.65% +6.56% +14.34% -27.13% +18.93% +0.46% +13.52% -28.66% +8.89% +10.00% +3.21% -20.22% -2.32% +16.08% +7.83% n/a